Most importantly, since the KO mice of MAFG did not show a strong phenotype [197], targeting MAFG as a therapeutic approach, as it has been previously done to restore cisplatin sensitivity in lung cancer cells through DNA aptamers [196], provides promising results and potential therapeutic strategies in the future. The gene discussed is MAFG; the disease is lung carcinoma.